Skip to content

Foundayo vs Wegovy: which suits whom?

By the glp1doses editorial team
Every number is checked against FDA labels and official price pages. How we check

The short answer

Foundayo vs Wegovy compares a daily tablet with a brand sold as a daily tablet and a weekly injection. Foundayo (orforglipron) is approved for weight reduction in adults. Wegovy (semaglutide) is approved for weight reduction, cardiovascular risk reduction and, for the injection, MASH. Self-pay is $149 to $299 a month for Foundayo, the same range for Wegovy tablets, and $349 for the Wegovy 2.4 mg pen.

Source: LillyDirect self-pay

Key takeaways

  • Both are approved for long-term weight reduction in adults. Only Wegovy's label adds cardiovascular and, for the injection, MASH uses.
  • Foundayo goes with or without food. The Wegovy tablet needs an empty stomach and a 30-minute wait.
  • Paying cash? Foundayo (LillyDirect) and Wegovy tablets (NovoCare) both run $149 to $299 a month.
  • On a strong CYP3A4 inhibitor or simvastatin, or have severe liver impairment? Ask about the limits on Foundayo's label.
  • No label converts a Wegovy dose into a Foundayo dose. Your prescriber decides where you start.

Foundayo vs Wegovy, side by side

From each FDA label and our verified price records
FoundayoWegovy
Active ingredientorforglipronsemaglutide
MakerEli Lilly and CompanyNovo Nordisk
FDA-approved uses
  • reduce excess body weight and maintain weight reduction long term in adults with obesity, or overweight with at least one weight-related comorbid condition
  • Reduce the risk of major adverse cardiovascular events in adults with established CV disease and either obesity or overweight (injection and tablets)
  • Reduce excess body weight and maintain weight reduction long term in adults and pediatric patients aged 12 years and older with obesity (injection)
  • Reduce excess body weight and maintain weight reduction long term in adults with overweight and at least one weight-related comorbid condition (injection and tablets)
  • Reduce excess body weight and maintain weight reduction long term in adults with obesity (tablets)
  • Treatment of noncirrhotic MASH with moderate to advanced liver fibrosis (F2 to F3) in adults, under accelerated approval (injection)
How it is takendaily (tablet)weekly (single-dose pen); daily (tablet)
Strengths0.8 to 17.2 mg0.25 to 25 mg
Label starting dose
  • 0.8 mg daily
  • 0.25 mg weekly
  • 1.5 mg daily
Cheapest verified self-pay$299 per fill at 17.2 mg
LillyDirect self-pay
$299 per fill at 25 mg
NovoCare self-pay
With covering commercial insurance$25 with the manufacturer card$25 with the manufacturer card
Medicare GLP-1 BridgeYes: Tablet (once daily)Yes: Single-dose pen (7.2 mg pen is branded WEGOVY HD); Tablet (once daily)
LabelRevised: 7/2026 (DailyMed version 10)Revised: 6/2026 (DailyMed version 19)
Foundayo: most common reactions on the label · Pool of two randomized, double-blind, placebo-controlled weight management trials (Trials 1 and 2) that included 3155 adults with obesity or overweight, with or without type 2 diabetes, treated with Foundayo once daily for up to 72 weeks plus a 2-week off-drug follow-up period.
Reaction17.2 mgPlacebo
Nausea35%10%
Diarrhea25%11%
Constipation24%9%
Vomiting24%4%
Abdominal pain14%7%
Dyspepsia13%4%
Wegovy: most common reactions on the label · Adults with obesity or overweight in 3 randomized, double-blind, placebo-controlled trials, treated with Wegovy 2.4 mg injection for up to 68 weeks plus a 7-week off-drug follow-up. The label shows '<1' for placebo eructation. The hypoglycemia row is for patients with type 2 diabetes not on insulin (Study 3: Wegovy N=403, placebo N=402). Abdominal pain, fatigue, gastritis and dysesthesia are grouped terms.
ReactionWegovy injection 2.4 mg once weeklyPlacebo
Nausea44%16%
Diarrhea30%16%
Vomiting24%6%
Constipation24%11%
Abdominal Pain20%10%
Headache14%10%

Each table comes from that medicine's own trials. The trials differ in who was studied and for how long, so the percentages are not a head-to-head comparison.

Foundayo and Wegovy are both approved for long-term weight reduction in adults, and both can be taken as a daily tablet. They’re different medicines, though. Foundayo is orforglipron, made by Eli Lilly, and comes only as a tablet. Wegovy is semaglutide, made by Novo Nordisk, and comes as a weekly injection and as a tablet.

Which one suits whom?

  • You want a tablet with no food or timing rules. The Foundayo label says to take it once daily, with or without food. The Wegovy tablet has to be taken in the morning on an empty stomach, followed by a 30-minute wait.
  • You’d rather inject once a week than take a tablet every day. Only Wegovy offers that.
  • You have established cardiovascular disease with obesity or overweight. Wegovy is approved to reduce cardiovascular risk in that group. Foundayo’s label has one use, weight reduction.
  • You take a strong CYP3A4 inhibitor or simvastatin, or have severe liver impairment. The Foundayo label has specific limits for each, described below. Raise them with your prescriber or pharmacist.
  • You’re paying cash. The two tablets cost about the same. The Wegovy pen costs more than either tablet at maintenance doses (the doses you stay on).
  • You’re on Medicare. Both are Bridge products at the same copay.

If you want a pill, the real question is which daily routine you’d keep up. Ask your prescriber what your other morning medicines mean for the Wegovy tablet’s 30-minute wait, and what your medicine list means for Foundayo’s limits.

What is each one approved for?

Foundayo is approved to reduce excess body weight and keep it off long term in adults with obesity, or with overweight and at least one weight-related condition. That’s its only approved use.

Wegovy shares that use and adds others: cardiovascular risk reduction in adults with established cardiovascular disease and obesity or overweight (injection and tablets), weight reduction in patients aged 12 and older with obesity (injection), and noncirrhotic MASH with moderate to advanced liver fibrosis (injection, under accelerated approval).

Each label says the medicine shouldn’t be used with another GLP-1 receptor agonist, so the two are alternatives. You wouldn’t take both.

How is each one taken?

Foundayo. One tablet once daily, with or without food, swallowed whole. Strengths are 0.8 mg, 2.5 mg, 5.5 mg, 9 mg, 14.5 mg, 17.2 mg. The label starts at 0.8 mg, raises the dose to 2.5 mg after at least 30 days and to 5.5 mg after at least another 30. From there, the dose may rise to 9 mg, 14.5 mg or 17.2 mg, each after at least 30 days, based on response and tolerability. The maximum is 17.2 mg once daily.

Wegovy tablets. One tablet once daily in the morning on an empty stomach with up to 4 ounces of water, swallowed whole. Then wait at least 30 minutes before food, drink or other oral medicines. Strengths are 1.5 mg, 4 mg, 9 mg, 25 mg, in 30-day steps: 1.5 mg, then 4 mg, then 9 mg, then the 25 mg maintenance dosage from day 91.

Wegovy pen. One injection once weekly, on the same day each week, at any time of day, with or without meals. Strengths are 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg, 7.2 mg, stepping up every 4 weeks to the usual maintenance dosage of 2.4 mg.

Three practical differences follow.

  • Other medicines. The Foundayo label caps the dose at 9 mg once daily if you take a strong CYP3A4 inhibitor (a type of medicine that slows how the body clears some drugs). It also says simvastatin shouldn’t exceed 20 mg once daily when taken with Foundayo. It isn’t recommended in severe liver impairment. Your pharmacist can check your medicine list against these.
  • Storage. Both tablets are kept at room temperature. The Wegovy pen is stored in the refrigerator, and can be kept at up to 86°F for up to 28 days before the cap is removed.
  • Moving between forms. Wegovy’s label lets adults move between the 2.4 mg injection and the 25 mg tablet on a stated schedule. See Wegovy pen to pill. Foundayo has one form.

The dosing guide shows every ladder, and the pen vs vial vs pill comparer sets pill against pen on cost.

What does each label report on weight?

Each label reports its own placebo-controlled trials.

  • Foundayo. In Trial 1, in adults without diabetes, mean (average) body-weight change at 72 weeks was -7.4% with 5.5 mg, -8.3% with 9 mg and -11.1% with 17.2 mg, versus -2.1% with placebo. The label notes that these data come from trials of an investigational orforglipron formulation (a study version, not the tablet sold today), shown as equivalent once-daily Foundayo dosages.
  • Wegovy tablets. In Study 7, a 64-week trial in adults without diabetes, mean body-weight change was -13.6% with the 25 mg tablets versus -2.4% with placebo.
  • Wegovy injection. In Study 2, a 68-week trial in adults without diabetes, it was -14.9% with 2.4 mg versus -2.4% with placebo.

That’s three trials, three lengths and three sets of participants, and one used a formulation that isn’t the marketed tablet. They don’t rank the medicines or predict your result.

What does each one cost?

On manufacturer self-pay:

Foundayo (LillyDirect). $149 a month for 0.8 mg and 2.5 mg, $199 for 5.5 mg, and $299 for 9 mg, 14.5 mg and 17.2 mg. For 14.5 mg and 17.2 mg, you keep that price only if you refill within 45 days of the previous fill. After that, it’s $349. The list price (the full price before any discount) is $649 a month.

Wegovy tablets (NovoCare). $149 a month for 1.5 mg, $199 for 4 mg, and $299 for 9 mg and 25 mg. No refill-window rule applies.

Wegovy pen (NovoCare). $199 a month for a new patient’s first two fills of 0.25 mg or 0.5 mg, then $349. It’s $349 for 1 mg, 1.7 mg and 2.4 mg, and $399 for 7.2 mg.

With commercial insurance that covers the drug. Each company’s savings card brings a fill to as little as $25. Neither can be used with Medicare, Medicaid or other government coverage.

Held for a full year at the top tablet dose, self-pay comes to $3,588 for Foundayo 17.2 mg with on-time refills and $3,588 for Wegovy 25 mg tablets. The cost calculator prices the climb to any dose, and the Foundayo cost and Wegovy cost pages list each route’s conditions.

How do insurance and Medicare treat them?

Commercial plans. Both are weight-management medicines, so the first question is whether your plan covers that class at all. Call the number on your insurance card and ask. Where it does, expect prior authorization (the plan’s approval before it pays), and expect the plan to prefer particular brands. The prior authorization guide explains the usual criteria.

Medicare. The Part D statute excludes drugs when used for weight loss, so Part D won’t normally pay for either one for that purpose. The Medicare GLP-1 Bridge is the temporary exception, and both are on its list: Foundayo tablets, the Wegovy pen and Wegovy tablets, each at a $50 copay for a one-month supply. Wegovy has an extra route Foundayo lacks, because CMS names Wegovy for cardiovascular risk reduction as a use coverable under Part D. The Bridge eligibility checker walks through the criteria.

How do the side effects compare?

Both labels carry a boxed warning headed “Risk of Thyroid C-Cell Tumors,” and both report mainly gastrointestinal (stomach and bowel) reactions. The tables come from separate trial programs, so each set of rates describes one medicine in its own trials. It isn’t a ranking.

Foundayo. In the pool of two placebo-controlled trials in adults with obesity or overweight, treated for up to 72 weeks, nausea was reported by 26, 34 and 35 percent of patients on 5.5 mg, 9 mg and 17.2 mg, against 10 percent on placebo. Constipation was reported by 20, 27 and 24 percent (placebo 9 percent), diarrhea by 21, 23 and 25 percent (placebo 11 percent) and vomiting by 13, 21 and 24 percent (placebo 4 percent). Across both trials, 8% of patients on Foundayo permanently stopped treatment because of adverse reactions, compared with 3% on placebo.

Wegovy. The label tables in our records are for the injection. In three placebo-controlled trials in adults with obesity or overweight, on 2.4 mg for up to 68 weeks, nausea was reported by 44 percent of patients (16 percent on placebo), diarrhea by 30 percent (16 percent), vomiting by 24 percent (6 percent) and constipation by 24 percent (11 percent). In those trials, 6.8% of patients on Wegovy and 3.2% on placebo permanently stopped treatment because of adverse reactions.

Both labels say gastrointestinal reactions were most frequent during dose escalation, while the dose was going up. The side effects guide covers the warnings.

Switching between Foundayo and Wegovy

The Foundayo label has no instructions for coming from another GLP-1 medicine. It gives its starting dose and nothing more. The Wegovy label’s switching section covers only moves between Wegovy’s own injection and tablets. No label matches a Wegovy strength to a Foundayo strength, and the milligram numbers of the two tablets are unrelated.

Your prescriber decides where you start, and when. The switching guide and the switching planner show what each label says and the cost on either side.

Frequently asked questions

Is Foundayo better than Wegovy?

The labels can't answer that. Foundayo's trials reported results at 72 weeks using an investigational formulation, the Wegovy tablet trial ran 64 weeks and the Wegovy injection trial 68 weeks. Different lengths and participants mean the results can't be ranked. The labels do differ clearly on approved uses, form and how each is taken.

What is the difference between Foundayo and the Wegovy pill?

They're different medicines: Foundayo contains orforglipron and the Wegovy pill contains semaglutide. Both are taken once daily. The Foundayo label says with or without food. The Wegovy label says to take the tablet in the morning on an empty stomach with up to 4 ounces of water, then wait at least 30 minutes before eating, drinking or taking other oral medicines.

Is Foundayo cheaper than Wegovy?

Against the Wegovy tablets, self-pay prices sit in the same range: Foundayo runs $149 to $299 a month and Wegovy tablets $149 to $299. Against the Wegovy pen, Foundayo is lower: the pen is $349 a month at 1 mg to 2.4 mg. Foundayo's two highest strengths need on-time refills to keep their price.

Does Medicare cover Foundayo and Wegovy?

Both are in the Medicare GLP-1 Bridge for weight management, at a $50 copay for a one-month supply for people who meet its criteria. The Bridge covers Foundayo tablets and both the Wegovy pen and Wegovy tablets. Separately, Part D can cover Wegovy when it's prescribed for cardiovascular risk reduction. Foundayo has no such second route.

Can I switch from Wegovy to Foundayo?

A prescriber can make the change, but the Foundayo label gives no instructions for switching from another GLP-1 medicine. It gives only its starting dose, 0.8 mg once daily. No label converts a Wegovy dose into a Foundayo dose. The Foundayo label also says use with another GLP-1 receptor agonist isn't recommended, so the two aren't overlapped.

Sources (32)

  1. 1.
    FDA label (DailyMed): Foundayo prescribing information, section 2.1
    “Take FOUNDAYO orally once daily, with or without food.”
  2. 2.
    FDA label (DailyMed): Foundayo prescribing information, section 2.1
    “Swallow tablets whole. Do not break, crush, or chew.”
  3. 3.
    FDA label (DailyMed): Foundayo prescribing information, section 2.1
    “The starting dosage is 0.8 mg orally once daily. After at least 30 days on the 0.8 mg dosage, increase the dosage to 2.5 mg once daily.”
  4. 4.
    FDA label (DailyMed): Foundayo prescribing information, section 2.1
    “The maximum dosage of FOUNDAYO is 17.2 mg once daily.”
  5. 5.
    FDA label (DailyMed): Foundayo prescribing information, section 2.2
    “The maximum dosage of FOUNDAYO is 9 mg once daily when used concomitantly with a strong CYP3A4 inhibitor [see Drug Interactions (7.1), Clinical Pharmacology (12.3)].”
  6. 6.
    FDA label (DailyMed): Foundayo prescribing information, section 7.2, Table 3
    “Do not exceed simvastatin 20 mg once daily when concomitantly used with FOUNDAYO.”
  7. 7.
    FDA label (DailyMed): Foundayo prescribing information, section 8.6
    “FOUNDAYO is not recommended for use in patients with severe hepatic impairment (Child-Pugh Class C) [see Clinical Pharmacology (12.3)].”
  8. 8.
    FDA label (DailyMed): Foundayo prescribing information, section 1
    “Concomitant use with another GLP-1 receptor agonist is not recommended.”
  9. 9.
    FDA label (DailyMed): Foundayo prescribing information, section 14
    “In these trials, the primary efficacy parameter was mean percent change in body weight after 72 weeks of treatment.”
  10. 10.
    FDA label (DailyMed): Foundayo prescribing information, section 14
    “This section of labeling presents efficacy data from administration of the investigational orforglipron formulation shown as equivalent dosages of once daily FOUNDAYO [see Dosage and Administration (2.1)].”
  11. 11.
    FDA label (DailyMed): Foundayo prescribing information, section 14, Table 6
    “Table 6: Changes from Baseline in Body Weight at Week 72 in Trials 1 and 2 in Patients with Obesity or Overweight with ≥1 Weight-related Comorbid Condition. % Change from baseline: Trial 1 Placebo once daily N = 949: -2.1; Trial 1 FOUNDAYO 5.5 mg once daily N = 723: -7.4; Trial 1 FOUNDAYO 9 mg once daily N = 725: -8.3; Trial 1 FOUNDAYO 17.2 mg once daily N = 730: -11.1; Trial 2 Placebo once daily N = 630: -2.5; Trial 2 FOUNDAYO 5.5 mg once daily N = 329: -5.1; Trial 2 FOUNDAYO 9 mg once daily N = 332: -7; Trial 2 FOUNDAYO 17.2 mg once daily N = 322: -9.6”
  12. 12.
    FDA label (DailyMed): Foundayo prescribing information, section 16.2
    “Store FOUNDAYO at room temperature 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C and 30°C (59°F and 86°F) [See USP Controlled Room Temperature].”
  13. 13.
    FDA label (DailyMed): Wegovy prescribing information, section 2.1
    “Take one WEGOVY tablet orally once daily on an empty stomach in the morning with water (up to 4 ounces). Do not take WEGOVY tablets with other liquids besides water”
  14. 14.
    FDA label (DailyMed): Wegovy prescribing information, section 2.1
    “After taking a WEGOVY tablet, wait at least 30 minutes before eating food, drinking beverages or taking other oral medications”
  15. 15.
    FDA label (DailyMed): Wegovy prescribing information, section 2.1
    “Swallow tablets whole. Do not split, crush, chew or dissolve in any solution.”
  16. 16.
    FDA label (DailyMed): Wegovy prescribing information, section 16
    “Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature]. Store and dispense WEGOVY tablets in the original bottle.”
  17. 17.
    FDA label (DailyMed): Wegovy prescribing information, section 16
    “Store the WEGOVY prefilled single-dose pen or single-dose syringe in the refrigerator from 2°C to 8°C (36°F to 46°F). If needed, prior to the pen or syringe cap removal, the pen can be kept from 8°C to 30°C (46°F to 86°F) up to 28 days.”
  18. 18.
    FDA label (DailyMed): Wegovy prescribing information, section 2.1
    “Administer WEGOVY injection once weekly, on the same day each week, at any time of day, with or without meals.”
  19. 19.
    FDA label (DailyMed): Wegovy prescribing information, section 1
    “Concomitant use of WEGOVY (semaglutide) tablets or WEGOVY (semaglutide) injection with other semaglutide-containing products or with any other GLP-1 receptor agonist is not recommended.”
  20. 20.
    FDA label (DailyMed): Wegovy prescribing information, section 2.5
    “One week after discontinuing WEGOVY 2.4 mg injection, initiate 25 mg of WEGOVY tablets orally once daily.”
  21. 21.
    FDA label (DailyMed): Wegovy prescribing information, section 2.5
    “The day after discontinuing WEGOVY tablets 25 mg once daily, initiate WEGOVY 2.4 mg subcutaneous injection once weekly.”
  22. 22.
    FDA label (DailyMed): Wegovy prescribing information, section 14.2, Table 11
    “After 64 weeks, treatment with WEGOVY 25 mg tablets resulted in a statistically significant reduction in body weight compared with placebo.”
  23. 23.
    FDA label (DailyMed): Wegovy prescribing information, section 14.2, Table 8
    “After 68 weeks, treatment with WEGOVY injection resulted in a statistically significant reduction in body weight compared with placebo. Greater proportions of patients treated with WEGOVY injection achieved 5%, 10% and 15% weight loss than those treated with placebo as shown in Table 8.”
  24. 24.
    Federal Register: Medicare and Medicaid Programs; Contract Year 2026 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, Medicare Cost Plan Program, and Programs of All-Inclusive Care for the Elderly (proposed rule, 89 FR 99340)
    “The statutory definition of a covered Part D drug at section 1860D-2(e)(2) of the Social Security Act (the Act) excludes certain drugs and uses—specifically, those that may be excluded by Medicaid under section 1927(d)(2) of the Act. This includes, at section 1927(d)(2)(A) of the Act, “agents when used for anorexia, weight loss, or weight gain.” Historically, drugs used for weight loss have been excluded from the definition of covered Part D drug, regardless of their use for treatment of individuals with obesity, and have been an optional drug benefit for Medicaid programs.”
  25. 25.
    CMS: Information for Part D Plans
    “Beneficiaries who are prescribed an eligible GLP-1 drug for a use that is coverable under the basic Medicare Part D benefit, regardless of whether the eligible GLP-1 drug is on the Part D plan’s formulary (e.g., Zepbound® for the treatment of moderate to severe obstructive sleep apnea (OSA) in adults with obesity; Wegovy® to reduce the risk of major adverse cardiovascular (CV) events in adults with established CV disease and either obesity or overweight) would not qualify for coverage of that eligible GLP-1 drug under the Medicare GLP-1 Bridge. Part D plan sponsors must continue to follow their existing formulary exception processes for these requests.”
  26. 26.
  27. 27.
  28. 28.
  29. 29.
  30. 30.
  31. 31.
  32. 32.